ESPAC-4: A Multicenter, International, Randomized Controlled Phase III Trial of Adjuvant Combination Chemotherapy of Gemcitabine (GEM) and Capecitabine (CAP), Versus Monotherapy Gemcitabine in Patients With Resected Pancreatic Ductal Adenocarcinoma

被引：0

作者：

Neoptolemos, J. P. ^{[1
]}

Palmer, D. ^{[1
]}

Ghaneh, P. ^{[1
]}

Valle, J. ^{[2
,3
]}

Cunningham, D. ^{[4
]}

Wadsley, J. ^{[5
]}

Meyer, T. ^{[6
]}

Anthoney, A. ^{[7
]}

Glimelius, B. ^{[8
]}

Falk, S. ^{[9
]}

Lind, P. ^{[10
]}

Izbicki, J. ^{[11
]}

Middleton, G. ^{[12
]}

Ross, P. ^{[13
]}

Wasan, H. ^{[14
]}

McDonald, A. ^{[15
]}

Crosby, T. ^{[16
]}

Psarelli, E. ^{[1
]}

Hammel, P. ^{[17
]}

Buechler, M. W. ^{[18
]}

机构：

[1] Univ Liverpool, Liverpool, Merseyside, England

[2] Univ Manchester, Manchester, Lancs, England

[3] Christie, Manchester, Lancs, England

[4] Royal Marsden Hosp, London, England

[5] Weston Pk Hosp, Sheffield, S Yorkshire, England

[6] Royal Free Hosp, London, England

[7] St James Univ Hosp, Leeds, W Yorkshire, England

[8] Uppsala Univ, Uppsala, Sweden

[9] Bristol Haematol & Oncol Ctr, Bristol, Avon, England

[10] Karolinska Univ Hosp, Stockholm, Sweden

[11] Univ Hamburg, Med Inst UKE, Hamburg, Germany

[12] Royal Surrey Cty Hosp, Guildford, Surrey, England

[13] Guys Hosp, London, England

[14] Hammersmith Hosp, London, England

[15] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[16] Velindre Hosp, Cardiff, S Glam, Wales

[17] Hop Beaujon, Clichy, France

[18] Heidelberg Univ, Heidelberg, Germany

来源：

PANCREAS | 2016年 / 45卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1529 / 1529

页数：1

共 50 条

[21] Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005
Wisniewski, Mathilde
Placide, Pierre-Alain
Granier, Sandra
Al Shatti, Yacoub
Al Qalaf, Shuaib
Bouattour, Mohamed
Lamuraglia, Michele
Hammel, Pascal
HEPATOBILIARY SURGERY AND NUTRITION, 2018, 7 (05) : 399 - 402
[22] APACT: Phase III, Multicenter, International, Open-Label, Randomized Trial of Adjuvant nab-Paclitaxel Plus Gemcitabine (nab-P/G) Versus Gemcitabine (G) for Surgically Resected Pancreatic Adenocarcinoma
Ko, A.
Reni, M.
Riess, H.
Pelzer, U.
O'Reilly, E. M.
Winter, J.
Oh, D. Y.
Li, C. P.
Tortora, G.
Chang, H. M.
Lopez, C. D.
Tabernero, J.
Van Cutsem, E.
Philip, P.
Goldstein, D.
Berlin, J. D.
Ferrara, S.
Li, M.
Lu, B.
Romano, A.
Marks, H.
Biankin, A.
Tempero, M. A.
PANCREAS, 2019, 48 (10) : 1464 - 1464
[23] A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer.
Neuhaus, P
Oettle, H
Post, S
Gellert, K
Ridwelski, K
Schramm, H
Zülke, C
Fahlke, G
Langrehr, J
Riess, H
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1092S - 1092S
[24] Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study)
Uesaka, Katsuhiko
Fukutomi, Akira
Boku, Narikazu
Kanemoto, Hideyuki
Konishi, Masaru
Matsumoto, Ippei
Kaneoka, Yuji
Shimizu, Yasuhiro
Nakamori, Shoji
Sakamoto, Hirohiko
Morinaga, Soichiro
Kainuma, Osamu
Imai, Koji
Sata, Naohiro
Hishinuma, Shoichi
Nakamura, Takayuki
Kanai, Michio
Hirano, Satoshi
Yoshikawa, Yukinobu
Ohashi, Yasuo
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[25] A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
Lee, Hee Seung
Chung, Moon Jae
Park, Jeong Youp
Bang, Seungmin
Park, Seung Woo
Kim, Ho Gak
Noh, Myung Hwan
Lee, Sang Hyub
Kim, Yong-Tae
Kim, Hyo Jung
Kim, Chang Duck
Lee, Dong Ki
Cho, Kwang Bum
Cho, Chang Min
Moon, Jong Ho
Kim, Dong Uk
Kang, Dae Hwan
Cheon, Young Koog
Choi, Ho Soon
Kim, Tae Hyeon
Kim, Jae Kwang
Moon, Jieun
Shin, Hye Jung
Song, Si Young
MEDICINE, 2017, 96 (01)
[26] Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan adjuvant study group of pancreatic cancer (JASPAC-01)
Maeda, Atsuyuki
Boku, Narikazu
Fukutomi, Akira
Kondo, Satoshi
Kinoshita, Taira
Nagino, Masato
Uesaka, Katsuhiko
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (03) : 227 - 229
[27] CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
Sinn, Marianne
Bahra, Marcus
Liersch, Torsten
Gellert, Klaus
Messmann, Helmut
Bechstein, Wolf
Waldschmidt, Dirk
Jacobasch, Lutz
Wilhelm, Martin
Rau, Bettina M.
Gruetzmann, Robert
Weinmann, Arndt
Maschmeyer, Georg
Pelzer, Uwe
Stieler, Jens M.
Striefler, Jana K.
Ghadimi, Michael
Bischoff, Sven
Doerken, Bernd
Oettle, Helmut
Riess, Hanno
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (29) : 3330 - +
[28] A phase II randomized double blind multicenter trial of gemcitabine (Gem) plus imexon (IMX) versus Gem plus placebo (P) in patients with chemotherapy-neive pancreatic adenocarcinoma (PC)
Cohen, S. J.
Zalupski, M. M.
Conkling, P.
Nugent, F. W.
Ma, W.
Modiano, M.
Pascual, R. A.
Lee, F.
Wong, L.
Hersh, E.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[29] APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).
Tempero, Margaret A.
Cardin, Dana Backlund
Goldstein, David
O'Reilly, Eileen Mary
Philip, Agop Philip
Riess, Hanno
Macarulla, Teresa
Yung, Lotus
Li, Mingyu
Lu, Brian D.
Biankin, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[30] Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma:: a randomized phase II trial
Scheithauer, W
Schüll, B
Ulrich-Pur, H
Schmid, K
Raderer, M
Haider, K
Kwasny, W
Depisch, D
Schneeweiss, B
Lang, F
Kornek, GV
ANNALS OF ONCOLOGY, 2003, 14 (01) : 97 - 104

← 1 2 3 4 5 →